Allergan and Actress Shay Mitchell Join Forces to Inspire Women to Know Their Birth Control | New 'BC Trivia' Quiz to Encourage Informed Conversations Around Contraception News By Allergan plc
news, events & stories

#1 News Source for the Creative People

   Welcome Guest | Login

Allergan and Actress Shay Mitchell Join Forces to Inspire Women to Know Their Birth Control | New 'BC Trivia' Quiz to Encourage Informed Conversations Around Contraception

Women's Lifestyle News By Allergan plc | Posted on June 10, 2018 11:38 AM

Allergan and Actress Shay Mitchell Join Forces to Inspire Women to Know Their Birth Control | Know Your Birth Control® Launches New 'BC Trivia' Quiz to Encourage Informed Conversations Around Contraception - PRNewsFoto/Allergan plc  

Women's Lifestyle News by Allergan plc : Allergan plc (NYSE: AGN), a leader in women's healthcare and the maker of Lo Loestrin® Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), today announced the launch of 'BC Trivia' featuring actress and new ambassador Shay Mitchell – a fun and engaging trivia quiz designed to educate young women about contraceptive options in a familiar way for its bold educational platform, Know Your Birth Control®.

In partnership with Allergan, Mitchell, known as one of the top names in the industry for her roles in several acclaimed movies and television shows, hopes to encourage women to have candid conversations about their contraceptive options with their healthcare providers, while simultaneously offering preliminary education.

"In conversations with my friends and family, it is constantly made clear to me that people are not speaking about birth control as much as they should be. When they do, the dialogue is riddled with misconceptions," said Mitchell. "At the very least, we should all know about the host of options that are available to us. Through my partnership with Allergan and Know Your Birth Control®, I hope we can bridge that gap together. It all starts by getting informed, talking to your doctor, and not being afraid to ask questions."

Launching last year, the program continues to evolve with new partners who are excited to contribute to the birth control conversation by offering informative facts and tips.

"In my practice, it is a consistent norm that birth control will be widely used, yet poorly understood," said Dr. Lakeisha Richardson, MD, a Mississipi-based OB/GYN and paid consultant of Allergan. "I always advocate that no question is too small when it comes to helping a patient make decisions about what is right for them. Through my upcoming work with Allergan, I look forward to channeling this approach, and to developing materials and resources that will help support women seeking information about contraceptive options."

On Mitchell's partnership with Know Your Birth Control®, Cindy Schwartz, Associate Vice President of Marketing at Allergan Women's Healthcare said, "We are delighted that Shay is joining us in this significant campaign. With her support and participation, we feel strongly that we will reach a wide network of women, encouraging many to take the initiative to speak to their doctors, and ultimately be in control of their birth control decisions."

To watch the quiz featuring Shay Mitchell, and to learn more about Know Your Birth Control®, visit www.KnowYourBirthControl.com.

What is Lo Loestrin® Fe?
Lo Loestrin Fe is a prescription birth control pill used for the prevention of pregnancy. If you are moderately obese, discuss with your healthcare provider whether Lo Loestrin Fe is appropriate for you.

IMPORTANT RISK INFORMATION
WARNING TO WOMEN WHO SMOKEDo not use Lo Loestrin Fe if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from birth control pills, including death from heart attack, blood clots, or stroke. This risk increases with age and the number of cigarettes you smoke.

Who should not take Lo Loestrin Fe?
Do not use Lo Loestrin Fe if you have or have had blood clots, history of heart attack or stroke, high blood pressure that medicine cannot control, breast cancer or any cancer that is sensitive to female hormones, liver disease or liver tumors, unexplained bleeding from the vagina, if you are or may be pregnant, or if you take Hepatitis C drugs containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, as this may increase levels of liver enzymes in the blood.

What else should I know about taking Lo Loestrin Fe?
Treatment with Lo Loestrin Fe should be stopped if you have a blood clot, and at least 4 weeks before and through 2 weeks after major surgery. You should not take Lo Loestrin Fe any earlier than 4 weeks after having a baby, or if you are breastfeeding. If you experience yellowing of the skin or eyes due to problems with your liver, you should stop taking Lo Loestrin Fe. If you are pre-diabetic or diabetic, your doctor should monitor you while using Lo Loestrin Fe. Your doctor should evaluate you if you have any significant change in headaches or irregular menstrual bleeding.

What are the most serious risks of taking Lo Loestrin Fe?
Lo Loestrin Fe increases the risk of serious conditions including blood clots, stroke, and heart attack. These can be life-threatening or lead to permanent disability.

What are the possible side effects of Lo Loestrin Fe?
The most common side effects reported by women taking Lo Loestrin Fe in a study were nausea/vomiting, headache, spotting or bleeding between menstrual periods, painful menstruation, weight change, breast tenderness, acne, abdominal pain, anxiety, and depression.

Birth control pills do not protect you against any sexually transmitted disease, including HIV, the virus that causes AIDS.

Please see the full Prescribing Information, including Boxed Warning, and Patient Information.

About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

Source: PR Newswire/Allergan plc

Website: http://www.allergan.com

HashTags: #Allergan #ShayMitchell #Actress #Women #Lifestyle #BirthControl

Click to Post Your Comments

Comments (0)

Click to view more comments

  • Beyoncé: 'Everything is Love' With Messika Paris | Beyoncé Shines in the Persian Drops Set, a Waterfall of more than 100 Carats of Diamonds

  • Novus Presents OCEANIA: A Nautical Inspired Line Of Men's Shoes | Footwear was created for men who are passionate about travel and with a genuine commitment to enjoy nature, culture and life

  • An Unexpected Approach: Modern Composer Conveys Classical Music Through Accessible, Immersive Experiences | Colorado Based Composer Aims to Expand Audiences' Appreciation of Classical Music

  • Chihuly glass sculptures, concerts under the stars help make summer shine at Biltmore this year

  • Wynn Las Vegas Announces Exclusive Retailers Joining Wynn Plaza

  • Holland America Line’s Nieuw Statendam - PRNewsFoto/Holland America Line

    Holland America Line and O, The Oprah Magazine Set Sail on a Three-Day Girls' Getaway Cruise Jan. 30, 2019, with Oprah Winfrey Aboard Nieuw Statendam

  • Metamathemagical - PRNewsFoto/Destination NSW 1000 Cranes - PRNewsFoto/Destination NSW Snugglepot and Cuddlepie - PRNewsFoto/Destination NSW

    Lights Out for Vivid Sydney 2018

  • Cool Memories and Hot Melodies | Explore Montana's music scene with exclusive local recommendations from Stephanie Quayle

  • Casio G-SHOCK Continues To Innovate Premium MR-G Line With Special Edition Connected Timepiece | Extremely Limited Edition Tsuiki Sword Guard Timepiece Will Be Available For Purchase Beginning in July

FashionAvenue.com, Inc.

FashionAvenue.com is a registered trademark & All other trademarks are property of their respective owners.

About us | User Agreement | Privacy Policy | Advertising & Sales

Copyright©2000-2018